Duloxetine: 4 agencies, 2004–2016
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
No agency in this archive has refused duloxetine: all 8 decisive outcomes across 4 agencies were positive or positive with restrictions.
Assessment has run over 11.4 years, from 11 Oct 2004 at SMC (Scotland) to 2 Mar 2016 at HAS (France).
No assessment is on file from PBAC (Australia), AWMSG (Wales), CIPM (Spain) and G-BA (Germany), each among the eight highest-volume agencies here.
Not every gap is a refusal: for duloxetine, 1 submission was never made — an outcome set by the company rather than the assessor.
Nothing has been added since 2016; on this evidence the file is dormant.
Against its own class, duloxetine is an outlier: 100% of its decisive outcomes were positive, where molecules sharing ATC class N06A average 71%.
SMC (Scotland) was first to assess duloxetine, on 11 Oct 2004; PHARMAC (New Zealand) did not open a file until 12 Nov 2009 — a wide spread of 5.1 years between the earliest and latest system to look at it.
Restriction is doing real work here: 4 of 8 decisive outcomes narrowed duloxetine to a subgroup rather than accepting or refusing it outright, at SMC (Scotland) and TLV (Sweden).
3 of the 4 agencies here assessed duloxetine more than once, TLV (Sweden) most often at 5 entries — repeat review is the norm for this molecule rather than the exception.
Coverage is narrow: only 4 of the 18 agencies here have assessed duloxetine.
The full ledger for duloxetine reads 4 recommended, 4 restricted, 1 non-submission and 1 other.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| HAS (France) | 2 Mar 2016 | Listing renewal (Transparency Committee) | SMR moderate | source |
| TLV (Sweden) | 8 May 2012 | Cymbalta ingår även fortsättningsvis i högkostnadsskyddet med begränsning | restricted subsidy | source |
| TLV (Sweden) | 21 Apr 2010 | Vi beslutar att begränsa subventionen för Cymbalta | restricted subsidy | source |
| PHARMAC (New Zealand) | 12 Nov 2009 | Depression - treatment-resistant major depressive disorder | PTAC advice: Cost Neutral · decision reached | source |
| SMC (Scotland) | 13 Oct 2008 | Generalised anxiety disorder | not recommended | source |
5 further decisions for duloxetine, across 3 agencies, are not shown here. They link to 4 further source documents.
Related molecules
- escitalopram — divergent outcome (recommended vs other) on a shared indication
- esketamine — same ATC class N06A — Psychoanaleptics
- venlafaxine — same ATC class N06A — Psychoanaleptics
- vortioxetine — same ATC class N06A — Psychoanaleptics
- paroxetine — same ATC class N06A — Psychoanaleptics
- mirtazapine — same ATC class N06A — Psychoanaleptics
Coverage: 10 decisions for duloxetine from 4 agencies, 2004 to 2016. Data to 7 Sep 2026. ATC class N06A — Psychoanaleptics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.